-+ 0.00%
-+ 0.00%
-+ 0.00%

Samsung Bioepis signed a biosimilar agreement of up to US$420 million with Teva.

智通财经·11/03/2026 08:01:11
语音播报
Samsung Bioepis signed a biosimilar agreement of up to US$420 million with Teva.